Microglia is a key player in the reduction of stroke damage promoted by the new antithrombotic agent ticagrelor

Paolo Gelosa, Davide Lecca, Marta Fumagalli, Dorota Wypych, Alice Pignieri, Mauro Cimino, Claudia Verderio, Malin Enerbäck, Elham Nikookhesal, Elena Tremoli, Maria P. Abbracchio, Luigi Sironi

Research output: Contribution to journalArticle

Abstract

The ADP-responsive P2Y12 receptor is expressed on both platelets and microglia. Clinical data show that ticagrelor, a direct-acting, reversibly binding P2Y12-receptor antagonist, reduces total cardiovascular events, including stroke. In our present study, we investigated the expression of P2Y12 receptors and the effects of ticagrelor on brain injury in Sprague-Dawley rats subjected to a permanent middle cerebral artery occlusion (MCAo). Rats were treated per os with ticagrelor 3 mg/kg or vehicle at 10 minutes, 22, and 36 hours after MCAo and killed after 48 hours. Immunofluorescence analysis showed an ischemia-related modulation of the P2Y12 receptor, which is constitutively expressed in Iba1+ resting microglia. After MCAo, activated microglia was mainly concentrated around the lesion, with fewer cells present inside the ischemic core. Ticagrelor significantly attenuated the evolution of ischemic damage-evaluated by magnetic resonance imaging (MRI) at 2, 24, and 48 hours after MCAo-, the number of infiltrating cells expressing the microglia/monocyte marker ED-1, the cerebral expression of proinflammatory mediators (interleukin 1 (IL-1), monocyte chemoattractant protein 1 (MCP-1), nitric oxide synthase (iNOS)) and the associated neurologic impairment. In transgenic fluorescent reporter CX3CR1-green fluorescent protein (GFP) mice, 72 hours after MCAo, ticagrelor markedly reduced GFP + microglia and both early and late infiltrating blood-borne cells. Finally, in primary cultured microglia, ticagrelor fully inhibited ADP-induced chemotaxis (P12-mediated microglia activation and chemotaxis.

Original languageEnglish
Pages (from-to)979-988
Number of pages10
JournalJournal of Cerebral Blood Flow and Metabolism
Volume34
Issue number6
DOIs
Publication statusPublished - 2014

Fingerprint

Fibrinolytic Agents
Microglia
Middle Cerebral Artery Infarction
Stroke
Chemotaxis
Green Fluorescent Proteins
Adenosine Diphosphate
Purinergic P2Y Receptor Antagonists
Chemokine CCL2
Ticagrelor
Interleukin-1
Nitric Oxide Synthase
Brain Injuries
Nervous System
Fluorescent Antibody Technique
Sprague Dawley Rats
Monocytes
Blood Cells
Blood Platelets
Ischemia

Keywords

  • microglia
  • middle cerebral artery occlusion
  • rat
  • ticagrelor

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Clinical Neurology
  • Neurology

Cite this

Microglia is a key player in the reduction of stroke damage promoted by the new antithrombotic agent ticagrelor. / Gelosa, Paolo; Lecca, Davide; Fumagalli, Marta; Wypych, Dorota; Pignieri, Alice; Cimino, Mauro; Verderio, Claudia; Enerbäck, Malin; Nikookhesal, Elham; Tremoli, Elena; Abbracchio, Maria P.; Sironi, Luigi.

In: Journal of Cerebral Blood Flow and Metabolism, Vol. 34, No. 6, 2014, p. 979-988.

Research output: Contribution to journalArticle

Gelosa, Paolo ; Lecca, Davide ; Fumagalli, Marta ; Wypych, Dorota ; Pignieri, Alice ; Cimino, Mauro ; Verderio, Claudia ; Enerbäck, Malin ; Nikookhesal, Elham ; Tremoli, Elena ; Abbracchio, Maria P. ; Sironi, Luigi. / Microglia is a key player in the reduction of stroke damage promoted by the new antithrombotic agent ticagrelor. In: Journal of Cerebral Blood Flow and Metabolism. 2014 ; Vol. 34, No. 6. pp. 979-988.
@article{3f27ae86dcf7433d806af04e08f44446,
title = "Microglia is a key player in the reduction of stroke damage promoted by the new antithrombotic agent ticagrelor",
abstract = "The ADP-responsive P2Y12 receptor is expressed on both platelets and microglia. Clinical data show that ticagrelor, a direct-acting, reversibly binding P2Y12-receptor antagonist, reduces total cardiovascular events, including stroke. In our present study, we investigated the expression of P2Y12 receptors and the effects of ticagrelor on brain injury in Sprague-Dawley rats subjected to a permanent middle cerebral artery occlusion (MCAo). Rats were treated per os with ticagrelor 3 mg/kg or vehicle at 10 minutes, 22, and 36 hours after MCAo and killed after 48 hours. Immunofluorescence analysis showed an ischemia-related modulation of the P2Y12 receptor, which is constitutively expressed in Iba1+ resting microglia. After MCAo, activated microglia was mainly concentrated around the lesion, with fewer cells present inside the ischemic core. Ticagrelor significantly attenuated the evolution of ischemic damage-evaluated by magnetic resonance imaging (MRI) at 2, 24, and 48 hours after MCAo-, the number of infiltrating cells expressing the microglia/monocyte marker ED-1, the cerebral expression of proinflammatory mediators (interleukin 1 (IL-1), monocyte chemoattractant protein 1 (MCP-1), nitric oxide synthase (iNOS)) and the associated neurologic impairment. In transgenic fluorescent reporter CX3CR1-green fluorescent protein (GFP) mice, 72 hours after MCAo, ticagrelor markedly reduced GFP + microglia and both early and late infiltrating blood-borne cells. Finally, in primary cultured microglia, ticagrelor fully inhibited ADP-induced chemotaxis (P12-mediated microglia activation and chemotaxis.",
keywords = "microglia, middle cerebral artery occlusion, rat, ticagrelor",
author = "Paolo Gelosa and Davide Lecca and Marta Fumagalli and Dorota Wypych and Alice Pignieri and Mauro Cimino and Claudia Verderio and Malin Enerb{\"a}ck and Elham Nikookhesal and Elena Tremoli and Abbracchio, {Maria P.} and Luigi Sironi",
year = "2014",
doi = "10.1038/jcbfm.2014.45",
language = "English",
volume = "34",
pages = "979--988",
journal = "Journal of Cerebral Blood Flow and Metabolism",
issn = "0271-678X",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Microglia is a key player in the reduction of stroke damage promoted by the new antithrombotic agent ticagrelor

AU - Gelosa, Paolo

AU - Lecca, Davide

AU - Fumagalli, Marta

AU - Wypych, Dorota

AU - Pignieri, Alice

AU - Cimino, Mauro

AU - Verderio, Claudia

AU - Enerbäck, Malin

AU - Nikookhesal, Elham

AU - Tremoli, Elena

AU - Abbracchio, Maria P.

AU - Sironi, Luigi

PY - 2014

Y1 - 2014

N2 - The ADP-responsive P2Y12 receptor is expressed on both platelets and microglia. Clinical data show that ticagrelor, a direct-acting, reversibly binding P2Y12-receptor antagonist, reduces total cardiovascular events, including stroke. In our present study, we investigated the expression of P2Y12 receptors and the effects of ticagrelor on brain injury in Sprague-Dawley rats subjected to a permanent middle cerebral artery occlusion (MCAo). Rats were treated per os with ticagrelor 3 mg/kg or vehicle at 10 minutes, 22, and 36 hours after MCAo and killed after 48 hours. Immunofluorescence analysis showed an ischemia-related modulation of the P2Y12 receptor, which is constitutively expressed in Iba1+ resting microglia. After MCAo, activated microglia was mainly concentrated around the lesion, with fewer cells present inside the ischemic core. Ticagrelor significantly attenuated the evolution of ischemic damage-evaluated by magnetic resonance imaging (MRI) at 2, 24, and 48 hours after MCAo-, the number of infiltrating cells expressing the microglia/monocyte marker ED-1, the cerebral expression of proinflammatory mediators (interleukin 1 (IL-1), monocyte chemoattractant protein 1 (MCP-1), nitric oxide synthase (iNOS)) and the associated neurologic impairment. In transgenic fluorescent reporter CX3CR1-green fluorescent protein (GFP) mice, 72 hours after MCAo, ticagrelor markedly reduced GFP + microglia and both early and late infiltrating blood-borne cells. Finally, in primary cultured microglia, ticagrelor fully inhibited ADP-induced chemotaxis (P12-mediated microglia activation and chemotaxis.

AB - The ADP-responsive P2Y12 receptor is expressed on both platelets and microglia. Clinical data show that ticagrelor, a direct-acting, reversibly binding P2Y12-receptor antagonist, reduces total cardiovascular events, including stroke. In our present study, we investigated the expression of P2Y12 receptors and the effects of ticagrelor on brain injury in Sprague-Dawley rats subjected to a permanent middle cerebral artery occlusion (MCAo). Rats were treated per os with ticagrelor 3 mg/kg or vehicle at 10 minutes, 22, and 36 hours after MCAo and killed after 48 hours. Immunofluorescence analysis showed an ischemia-related modulation of the P2Y12 receptor, which is constitutively expressed in Iba1+ resting microglia. After MCAo, activated microglia was mainly concentrated around the lesion, with fewer cells present inside the ischemic core. Ticagrelor significantly attenuated the evolution of ischemic damage-evaluated by magnetic resonance imaging (MRI) at 2, 24, and 48 hours after MCAo-, the number of infiltrating cells expressing the microglia/monocyte marker ED-1, the cerebral expression of proinflammatory mediators (interleukin 1 (IL-1), monocyte chemoattractant protein 1 (MCP-1), nitric oxide synthase (iNOS)) and the associated neurologic impairment. In transgenic fluorescent reporter CX3CR1-green fluorescent protein (GFP) mice, 72 hours after MCAo, ticagrelor markedly reduced GFP + microglia and both early and late infiltrating blood-borne cells. Finally, in primary cultured microglia, ticagrelor fully inhibited ADP-induced chemotaxis (P12-mediated microglia activation and chemotaxis.

KW - microglia

KW - middle cerebral artery occlusion

KW - rat

KW - ticagrelor

UR - http://www.scopus.com/inward/record.url?scp=84901829182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901829182&partnerID=8YFLogxK

U2 - 10.1038/jcbfm.2014.45

DO - 10.1038/jcbfm.2014.45

M3 - Article

C2 - 24643079

AN - SCOPUS:84901829182

VL - 34

SP - 979

EP - 988

JO - Journal of Cerebral Blood Flow and Metabolism

JF - Journal of Cerebral Blood Flow and Metabolism

SN - 0271-678X

IS - 6

ER -